RSV immunisation programme resumes

Imported from official source

Announcement

Safety Classified by Officially

With autumn approaching, the RSV immunisation programme is resuming today, in which babies receive an injection as protection against RSV. This protects them from serious RSV infections, which are most prevalent in autumn and winter. Babies receiving an injection are 80% less likely to end up in hospital as a result of an RSV infection. The injection has been offered as part of the National Immunisation Programme to all babies up to the age of one since 2025.

RSV causes respiratory infections such as the common cold and can be particularly dangerous for young babies. They may experience shortness of breath or develop pneumonia. Prior to the injection’s introduction, between 1,500 and 3,000 babies were admitted to hospital each year with an RSV infection.

More than three-quarters of babies were immunised against RSV over the past year. Babies receiving the injection were 80% less likely to be hospitalised as a result of an RSV infection than those not receiving the injection. This is evident from the initial findings of a study carried out in ten Dutch hospitals. As a result, children’s hospitals were under far less pressure than in previous years. Other countries that also introduced the antibody injection, such as Spain, Portugal and Belgium reported 80% fewer hospital admissions as a result of an RSV infection.

The injection has few side effects. Research (in Dutch) by Lareb, a centre that monitors adverse drugs reactions, showed that the majority of babies had no symptoms last year following an injection. If babies did experience symptoms, these usually entailed ‘increased crying’ and ‘irritability’.    

The RSV injection does not involve vaccination but immunisation. As the injection contains antibodies against the virus, a baby’s immune system does not need to produce these antibodies itself, as it does when receiving a vaccination. The injection offers almost immediate protection that lasts around six months.

Date of birth determines the timing of the injection

This is an extract. The publication continues at the source.

Source: RIVM.

Read the original at the source: https://www.rivm.nl/en/news/rsv-immunisation-programme-resumes

Officially imported this from RIVM’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.

Provenance

Organization
RIVM — imported from official source
Official source
https://www.rivm.nl/en/news/rss.xml RSS
Imported
October 03, 2026 20:38
Versions
1 recorded
Identity
https://www.rivm.nl/en/news/rsv-immunisation-programme-resumes

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.